Lakefront Biotherapeutics N.V.
LKFTHealthcare|Biotechnology|BE
$33.45
-0.11 (-0.33%)
DCF Value
$50.09
Tangible Book / Share
$49.36
Graham Number
$90.77
Cash / Share
$45.26
About
Lakefront Biotherapeutics NV, formerly Galapagos NV, is a biotechnology company that focuses on transforming patient outcomes through scientific innovation. It is dedicated to building a pipeline of medicines for patients with serious diseases in therapeutic areas of unmet need, prioritizing oncology and immunology & inflammation programs. The company's clinical-stage portfolio is anchored by potential first-in-class treatments for autoimmune diseases.
Stock Price
+7.2%(1Y)
1M
+13.4%
3M
+23.9%
6M
+17.0%
YTD
+2.3%
1Y
+3.1%
3Y
-8.9%
5Y
-41.4%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$2.19B
Employees452
CEOHenry Gosebruch
IPO DateMay 5, 2005
Beta0.12
52-Week Range$25.68 – $36.24
Avg Volume257,873
ExchangeNASDAQ
Websitelakefrontbio.com
Ownership
Float62.5%
Shares Outstanding65.5M
Peers
Recent News
Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?
Nov 6, 2026 · zacks.com
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
Nov 4, 2026 · globenewswire.com
Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors
Nov 2, 2026 · globenewswire.com
Oncocyte (NASDAQ:IMDX) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Head-To-Head Analysis
Oct 22, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:19 AM